Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, is reporting on its second and third quarter of 2022. According to the company, the filing, which includes financial results along with operation highlights, brings Vivos current on SEC filings for NASDAQ stock market purposes. The reported stated that there have been no restatements of the June and September 2021 quarter results as a result of the company’s conclusions; consequently, Vivos is unable to make direct results comparisons between Q2 and Q3 2022 and the same quarters in 2021 because of the changes in application of the company’s revenue recognition policies between these periods. The report went on to observe that this inability would not continue in 2023 and that direct comparisons between 2023 and 2022 would be possible. “We are pleased to finally report our second and third quarter results and to have the revenue recognition review process behind us,” said Vivos chair and CEO Kirk Huntsman. “We are even more pleased that the net effect of this review is relatively minimal. While we continued to face some headwinds in 2022, we believe we have reacted prudently. We can now report that through a series of cost reduction initiatives, operational streamlining, and new revenue opportunities, we are moving towards our goal of achieving positive cash flow operations in the next 12 to 18 months.”
To view the full press release, visit https://ibn.fm/AREhp
About Vivos Therapeutics Inc.
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) as well as snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution. It has proven effective in the treatment of more than 31,000 patients worldwide by more than 1,650 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the tissues that comprise a patient’s upper airway and palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos Method. For more information about this company, visit www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork